Publicacións nas que colabora con Juan Carlos Hernández Boluda (20)

2024

  1. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

  2. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

  3. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia

    Leukemia

  4. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis

    American Journal of Hematology

2023

  1. Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia

    HemaSphere, Vol. 7, Núm. 8, pp. E936

  2. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

    Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681

  3. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

    HemaSphere, Vol. 7, Núm. 1, pp. E818

  4. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

    Cancers, Vol. 15, Núm. 4

2022

  1. Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry

    Leukemia Research, Vol. 115

  2. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT

    Bone Marrow Transplantation, Vol. 57, Núm. 3, pp. 416-422

  3. Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT (Bone Marrow Transplantation, (2022), 57, 3, (416-422), 10.1038/s41409-021-01553-x)

    Bone Marrow Transplantation

  4. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2231-2239

  5. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis

    British Journal of Haematology, Vol. 199, Núm. 4, pp. 529-538

  6. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270

  7. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

    Cancer, Vol. 128, Núm. 13, pp. 2441-2448

2021

  1. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

    Blood Cancer Journal

  2. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study

    European Journal of Haematology, Vol. 106, Núm. 3, pp. 371-379

2020

  1. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model

    Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 12, pp. 2237-2244

2019

  1. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients

    Annals of Hematology, Vol. 98, Núm. 2, pp. 321-330

2014

  1. Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain

    Journal of Medical Economics, Vol. 17, Núm. 6, pp. 435-441